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Asymptomatic arotid artery stenosis (ACS) is com- 
mon. 1 Assuming a European population of around 500 
million people, about 4 million have stenoses of 
60-99%. About 1 million strokes occur each year, but 
only 5-10% (50-100 000) are attributable to carotid 
artery disease. 2 By operating on all 4 million with 
ACS, we might prevent 4% of first-in-a-lifetime 
strokes, but the cost would be prohibitive. 3"4 Carotid 
endarterectomy (CEA) would become the commonest 
vascular operation, more common than coronary 
bypass grafting (which is usually performed for 
symptoms or when significant danger is demonstrated 
on exercise testing). Although safer than CEA per- 
formed after stroke, 5the total morbidity and mortality 
following a policy of prophylactic CEA might even- 
tually equal, or even  exceed that of coronary 
surgery. 
In a recent leading article in this journal, 6Robicsek 
reviewed the results of the Asymptomatic Carotid 
Artery Study (ACAS). 7 In that study 1662 patients 
with 60-99% ACS were randomised to medical or 
surgical treatment. Patients and surgeons had been 
carefully chosen to minimise operative risk. After a 
mean follow-up of 2.7 years, a statistically significant 
result favouring surgery (for men only) s was obtained. 
During the first year of follow-up, the risk of operation 
exceeded that of stroke. The overall risk of stroke (any 
stroke, not disabling stroke) was reduced in the 
surgical group from ~ 2% to N 1% per year. No higher 
risk sub-group could be identified, but only 5% 
patients entered had 90-99% stenosis. The conclusion, 
that "patients with > 60% obstruction to the internal 
carotid flow should undergo carotid endarterectomy, 
even if they are asymptomatic, given experienced 
vascular surgical facilities with low morbidity and 
mortality rates" did not convince some of their own 
collaborators, 9 but effectively closed the study. 
At present, about 40% CEAs in the U.S. (and ~ 20% 
in Europe 1°) are done for ACS, and, following ACAS, 
this may now increase, allowing pride in this well 
conducted, but "unreal" study, to reinforce surgeons' 
prejudice that CEA should be used in these patients as 
a prophylactic procedure. The real measure of success- 
ful CEA would be a significant reduction in disabling 
strokes and deaths, the true end-points, and ACAS did 
not prove that these could be reduced by prophylactic 
CEA. Before ACAS, some insurance companies in the 
U.S. had refused to cover operations for ACS. Now 
insurance may be confined to covering operations 
undertaken i certain units, or performed by surgeons 
who have track records howing that they can perform 
the operation with < 3% mortality and morbidity. For 
newly qualified vascular surgeons the most attractive 
procedures with which to build a track record are 
those for ACS. 
It will never be possible to re-run the ACAS in the 
U.S. Millions of dollars were spent and a "statistically 
significant" result was obtained. But, in Europe, we 
can continue to evaluate operation for ACS. All 
surgeons need to be able to operate for asymptomatic, 
as well as symptomatic disease, but only when the 
risks of disabling stroke or death with medical 
treatment alone exceed those of operation. "Higher 
risk" groups need to be identified, not just by natural 
history studies (which often exclude patients appro- 
priate for operation) but by randomised controlled 
trial. Estimating the numbers needed to obtain a 
"significant" result has been flawed and trials have 
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stopped prematurely. By recruiting large numbers, the 
European Carotid Surgery Trial (ECST) n (and NAS- 
CET) 12 succeeded in identifying a high risk group of 
symptomatic patients with 70-99% stenosis, in whom 
3-4 prophylactic operations would prevent one disa- 
bling stroke. The results of ACAS showed that 85 
operations were needed to avoid one non-disabling 
stroke; with a larger trial, it should be possible to find 
a smaller, higher risk group of patients in whom, at 
lower cost, disabling stroke could be prevented. 
One trial of ACS is still recruiting patients. The 
Asymptomatic Carotid Surgery Trial (ACST) includes 
collaborating surgeons from Europe (and other coun- 
tries). 13 These surgeons have track records which are 
comparable with those obtained for ECST and NAS- 
CET, and have sufficient uncertainty about the value 
of prophylactic CEA to enable them to consider 
randomising patients to either appropriate best medi- 
cal treatment (BMT) or BMT and surgery. Over 1200 
patients have been entered into ACST during the first 
3 years. At randomisation, the presence of potential 
"risk factors" is noted; these include fight stenosis in 
Duplex, contralateral occlusion, soft plaque and brain 
scan infarction (CT or Magnetic resonance). Newer 
ultrasound techniques (Duplex, rather than continu- 
ous wave) are used to measure stenosis. ACST now 
has a greater number (and proportion) of patients with 
very tight stenosis (80-99%) than ACAS; (676 patients 
(55%) compared with 499 (30%)). Mean follow-up for 
patients in ACST is still less than 1 year, and many 
more will be needed to obtain a definitive result. 
Recruiting continues, and new collaborators are wel- 
comed. The Data Monitoring Committee recently 
urged that recruitment should continue. 
Over 3000 patients have now been entered in four 
asymptomatic trials. 7'13-15 Although Hennerici et al. 
expressed doubt about the population sample in 
ACAS, 16 in all four trials the patients are similar for 
age (64-68 years), sex (60-73% men, except VA trial - -  
all men), diabetes (21-30%), hypertension (60-64%), 
contralateral carotid occlusion (8-12%) and history of 
contralateral CEA (20-27%). It does now seem likely 
that some patients with ACS may benefit from 
prophylactic surgery. However, the ACAS results are 
of limited value when identifying individuals at risk 
of disabling stroke, or in planning a cost-effective 
policy for stroke prevention. Prejudice in favour of 
surgery will need to be confirmed by ACST identify- 
ing group(s) at higher stroke risk. This will only be 
possible if neurologists and surgeons upport ACST, 
and recruit enough patients to produce a sensible 
result. 
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